fda tirzepatide update today Breaking News: OFA Challenges on Shortage Ruling FDA confirms tirzepatide shortage is

The pivotal reference is the phase 2 obesity trial by Jastreboff and colleagues, published in the New England Journal of Medicine in 2023: a double-blind, randomized, placebo-controlled, dose-ranging study of 338 adults with obesity, or overweight with a weight-related condition, randomized to retatrutide (1, 4, 8, or 12 mg) or placebo

The use of elecoglipron was associated with additional exploratory changes beyond weight loss

Sideeffect rates were similar between saffron and placebo groups

Enhances mitochondrial function for overall cellular vitality

Wegovy is a once-weekly injection

In August 2024, Fox News applauded it as beneficial for the brain and liver, citing its high antioxidant content